Literature DB >> 2839432

Role of cell-mediated immunity in spontaneous regression of plane warts.

T T Rogozinski1, S Jablonska, M Jarzabek-Chorzelska.   

Abstract

Human papillomavirus-induced plane warts most often occur in the second decade of age. Afterward, they either spontaneously regress or are eradicated in the course of various treatments. As proved by in vivo and in vitro tests as well as clinical observations, they most often affect and persist longer in immunocompromised hosts. In this work it was confirmed that specific-ie, anti-HPV-directed, cell-mediated immunologic response plays a role in spontaneous regression of plane warts and that preservation of nonspecific immunity is prerequisite for spontaneous regression of plane warts.

Entities:  

Mesh:

Year:  1988        PMID: 2839432     DOI: 10.1111/j.1365-4362.1988.tb02362.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

Review 1.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

2.  A simple method for the propagation of cervical lymphocytes.

Authors:  A B Moscicki; S D Hunter; S Garland; M Quinn; S M Crowe; K Shortman; D Stites
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

3.  Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.

Authors:  Shreya Kanodia; Diane M Da Silva; Tigran Karamanukyan; Lies Bogaert; Yang-Xin Fu; W Martin Kast
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

Review 4.  Pathogenesis of genital HPV infection.

Authors:  A Schneider
Journal:  Genitourin Med       Date:  1993-06

5.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

6.  HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis.

Authors:  Colin M Gelder; O Martin Williams; Keith W Hart; Siôn Wall; Gareth Williams; Duncan Ingrams; Peter Bull; Mike Bunce; Ken Welsh; Sara E F Marshall; Leszek Borysiewicz
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 7.  Immunomanipulative strategies for the control of human papillomavirus associated cervical disease.

Authors:  R W Tindle
Journal:  Immunol Res       Date:  1997       Impact factor: 4.505

8.  Efficacy of Myrtus communis L. and Descurainia sophia L. Versus Salicylic Acid for Wart Treatment.

Authors:  Elham Ghadami Yazdi; Mohamad Bagher Minaei; Fataneh Hashem Dabaghian; Mohamad Ebrahim Zadeh Ardakani; Ali Mohammad Ranjbar; Mohamad Rastegari; Ali Ghadami Yazdi
Journal:  Iran Red Crescent Med J       Date:  2014-10-05       Impact factor: 0.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.